Town & Country Bank & Trust CO dba First Bankers Trust CO Grows Position in Danaher Co. (NYSE:DHR)

Town & Country Bank & Trust CO dba First Bankers Trust CO grew its position in Danaher Co. (NYSE:DHR) by 7.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 10,550 shares of the conglomerate’s stock after buying an additional 743 shares during the period. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Danaher were worth $2,422,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Coronation Fund Managers Ltd. lifted its position in Danaher by 29.9% during the second quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock valued at $1,596,000 after purchasing an additional 1,470 shares during the period. Ascent Group LLC grew its position in Danaher by 30.2% during the second quarter. Ascent Group LLC now owns 2,205 shares of the conglomerate’s stock valued at $551,000 after buying an additional 512 shares during the period. Creative Planning raised its position in Danaher by 6.0% in the second quarter. Creative Planning now owns 122,591 shares of the conglomerate’s stock worth $30,629,000 after acquiring an additional 6,969 shares during the period. NewEdge Advisors LLC boosted its stake in shares of Danaher by 36.9% during the 2nd quarter. NewEdge Advisors LLC now owns 49,460 shares of the conglomerate’s stock worth $12,357,000 after acquiring an additional 13,338 shares during the last quarter. Finally, Quarry LP increased its stake in shares of Danaher by 250.6% in the 2nd quarter. Quarry LP now owns 298 shares of the conglomerate’s stock worth $74,000 after purchasing an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.9 %

Danaher stock opened at $250.51 on Tuesday. The firm has a market cap of $180.94 billion, a P/E ratio of 47.81, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average of $235.33 and a two-hundred day moving average of $253.62. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is presently 20.61%.

Analyst Ratings Changes

A number of research analysts recently issued reports on DHR shares. Stephens reiterated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Barclays lowered their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup lowered their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, Guggenheim began coverage on shares of Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.